Evidence map›Paper›PMID 42479904›Full record

ArticleHematological oncology2026

Clinical Impact of BTK Inhibitor Exposure in LymphGen-Defined MCD Diffuse Large B-Cell Lymphoma.

Shiyu Jiang, Yizhen Liu, Ran Wei, Wenhao Zhang, Longlong Bao, Jia Jin, Fangfang Lv, Chuanxu Liu, Xiaojian Liu, Hui Sun and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hematological oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shiyu JiangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yizhen LiuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Ran WeiDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Wenhao ZhangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Longlong BaoDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Jia JinDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Fangfang LvDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Chuanxu LiuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiaojian LiuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID https://orcid.org/0000-0002-8884-4448
Hui SunDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Jiachen WangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Rong TaoDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Junning CaoDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiaoyan ZhouDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Qunling ZhangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.

Funding

Chinese Society of Clinical Oncology Chaoyang Oncology Research Fund Project Y-Young2024-0156Clinical Research Plan of Shanghai Hospital Development Center SHDC2020CR3046BClinical Research Special Project of Shanghai Municipal Health Commission 20244Y0073Innovation Program of Shanghai Science and Technology Committee 20Z11900300National Natural Science Foundation of China 81870155National Natural Science Foundation of China 82400234National Natural Science Foundation of China 82470189
6 · The paper itself

Abstract

The molecular subtype characterized by co-occurring MYD88 and CD79B alterations (MCD) represents a biologically distinct subset of diffuse large B-cell lymphoma (DLBCL) with chronic active B-cell receptor signaling and a high risk of central nervous system (CNS) involvement. The clinical impact of Bruton tyrosine kinase inhibitors (BTKi) in this subtype remains unclear. We retrospectively analyzed 155 patients with newly diagnosed DLBCL harboring genetic features consistent with the MCD subtype. At a median follow-up of 34.1 months, the estimated 3-year progression-free survival (PFS) rate was 76.1%. BTKi exposure (n = 56) was associated with significantly improved PFS compared with no BTKi exposure (3-year PFS: 93.8% vs. 66.6%, p < 0.001) and remained independently associated with improved PFS after adjustment for IPI risk (HR 0.16, p < 0.001). Overall survival did not differ significantly between groups. Notably, all 15 CNS relapse events occurred in patients who did not receive BTKi, whereas no CNS relapse was observed in the BTKi-treated group. BTKi exposure was independently associated with a markedly reduced risk of CNS relapse (HR 0.06, p = 0.002) after adjustment for CNS-IPI risk and CNS prophylaxis. These findings suggest that BTK inhibition may improve outcomes and mitigate CNS relapse in MCD DLBCL.

Indexed as

Agammaglobulinaemia Tyrosine KinaseLymphoma, Large B-Cell, DiffuseProtein Kinase InhibitorsAdultAgedAged, 80 and overCD79 AntigensCentral Nervous System NeoplasmsFemaleHumansMaleMiddle AgedRetrospective StudiesSurvival RateYoung AdultAgammaglobulinaemia Tyrosine KinaseBTK protein, humanCD79 AntigensCD79B protein, humanProtein Kinase InhibitorsBCR signalingBTK inhibitor introductionCNS relapsediffuse large B‐cell lymphomasurvival

Identifiers

PMID42479904
PMCPMC13387721

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.